From 2011.igem.org

Revision as of 09:20, 22 August 2011

Safety

Would any of your project ideas raise safety issues in terms of: researcher safety,public safety, or environmental safety?

The chassis and parts we will be working with are not inherently dangerous and generally considered safe to work with. In addition, we will be working in established laboratories with safety protocols firmly in place that we will be following. We will be using personal protective equipment where applicable and ensure that there is no accidental release that could endanger public or environmental safety.

Do any of the new BioBrick parts (or devices) that you made this year raise any safety issues? If yes, did you document these issues in the Registry? How did you manage to handle the safety issue? How could other teams learn from your experience?

We have not yet designed new BioBrick parts. However, the proteins we are planning to work with are not dangerous for humans or the environment. Should such issues arise against expectations, we will deal with the safety issues and thoroughly document them on the Registry.

Is there a local biosafety group, committee, or review board at your institution? If yes, what does your local biosafety group think about your project? If no, which specific biosafety rules or guidelines do you have to consider in your country?

There is a biosafety group at our university and no work on the project will commence before it has been approved by this group.

Do you have any other ideas how to deal with safety issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?

Unfortunately it is too early in the project to answer this question. However, we will be addressing these issues throughout our project.

1. Would the materials used in your project and/or your final product pose:
a. Risks to the safety and health of team members or others in the lab?
No, we are not using any materials that pose risk to anyone’s safety or health. We are only working with level 1 safety organisms and are not working with any toxic or otherwise dangerous materials. The products that will be produced by our bacteria are also not dangerous to humans.

b. Risks to the safety and health of the general public if released by design or accident?
No, our final product is an engineered E. coli producing auxin and expressing a plant exudate-responsive chemoreceptor. We have used the harmless E. coli K12 strain, which would not pose any threat to the public if released. The containment switch would pose a risk to any naturally occurring bacteria.

c. Risks to environmental quality if released by design or accident?
Yes. From consulting Dr Alexandru Milcu, an ecology expert, we have confirmed that secretion of natural indole-3-acetic acid into soil would not pose any large-scale threat to its biodiversity. The only organism it may affect is the earthworm. To test for any harmful effects of auxin on earthworms we are conducting experiments in soil containing different concentrations of synthetic auxin and worms. Auxin secretion in the soil may have harmful effects on naturally occurring soil bacteria.

d. Risks to security through malicious misuse by individuals, groups or states?
No. The auxin indole-3-acetic acid is detrimental for plants when supplied in very high concentrations. However, this is very unlikely to occur in nature as the IaaH-IaaM pathway we are engineering into our bacteria has a natural negative feedback loop. Our modelling has shown that a dangerous concentration of auxin should not be reached and we will also be confirming this in the wet lab.

Please explain your responses (whether yes or no) to these questions.

Specifically, are any parts or devices in your project associated with (or known to cause):
- pathogenicity, infectivity, or toxicity?
No. The auxin producing pathway occurs naturally in soil bacteria. While it can occur in plant pathogens, it is also used by plant symbionts and is not inherently dangerous and should not promote pathogenicity to the plants. None of the parts we are engineering promote infectivity or toxicity.

- threats to environmental quality?
No. Auxin secretion may favour some plants over others and this may skrew the population in affected areas, we are targeting areas that already have degraded soil and reduced biodiversity. The auxin should therefore not negatively influence the environment.

- security concerns?
No. There should not be any security concerns for any of the parts we are engineering. None of the parts should be damaging or a threat to security.

2. If your response to any of the questions above is yes:
a. Explain how you addressed these issues in project design and while conducting laboratory work.
We have addressed the issues by making doing various experiments on Arabidopsis thaliana and earthworms to see the effects of different auxin concentrations. This will inform our design by telling us how much auxin our bacteria should be able to produce with the help of modelling. Furthermore, to avoid horizontal gene transfer, we have come up with a design for a containment module. This module will make it so that if the auxin genes are ever transferred to any bacteria other than our own they will also be transferred with a holin and endolysin gene. These genes will lyse any cells that have obtained our plasmid.

b. Describe and document safety, security, health and/or environmental issues as you submit your parts to the Registry.

3. Under what biosafety provisions will / do you operate?
a. Does your institution have its own biosafety rules and if so what are they? Provide a link to them online if possible.
Imperial College does have its own biosafety rules. These rules limit the use of infective and GM modified organisms to certified laboratories and state the requirement to get approval for work with them and the requirement to dispose of the organisms appropriately and report any accidental release and accidents to the Health and Safety department. The policy can be found at http://www3.imperial.ac.uk/safety/policies/individualpolicies/pc-11dangerouspathogens. Another, more comprehensive outline of how to deal with specific biological agents can be found at http://www3.imperial.ac.uk/safety/subjects/biosafety.

b. Does your institution have an Institutional Biosafety Committee or equivalent group? If yes, have you discussed your project with them? Describe any concerns or changes that were made based on this review.
Yes, there is a biosafety committee at our institution and we have discussed our project with them. Following their advice, we used plastic rather than glass tubes for our worm experiment and prepared E coli solutions for plant root experiments in the labs we are using rather than in the plant room to prevent exposure of other plants to our E coli.

c. Will / did you receive any biosafety and/or lab training before beginning your project? If so, describe this training.
Before we were allowed into the lab we received a lab induction from our advisor (James Field) as well as the lab technicians. In this induction we were shown the proper ways of waste disposal and were also shown where the fume hoods are and the proper ways for handling GMO's. We were also given an induction for the plant lab and were told how to handle GM plants as well. We were also told where the emergency exits are and the proper assembly point in case of a fire.

d. Does your country have national biosafety regulations or guidelines? If so, provide a link to them online if possible.
There are national biosafety regulations in Britain. The full list can be found at http://www.hse.gov.uk/biosafety/biologagents.pdf

4. OPTIONAL QUESTION: Do you have other ideas on how to deal with safety or security issues that could be useful for future iGEM competitions? How could parts, devices and systems be made even safer through biosafety engineering?
We have designed a novel containment switch: the BacTrap. This device is able to kill non-engineered bacteria that take up the genetically engineered plasmid, thereby ensuring containment of the GM plasmid to engineered strains of bacteria.